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twice-daily) or Augmentin ES-600, are approved.
These high-dose formulations provide an amoxy-
cillin T > MIC of 46–49% of the dosing interval
for isolates with amoxycillin MICs of 4 mg ⁄L,
thereby providing coverage for an even larger
percentage of PRSP isolates.
The efﬁcacy of amoxycillin against PRSP has
also been demonstrated in the clinic. In a large
phase III clinical programme that included stud-
ies of community-acquired pneumonia, acute
bacterial sinusitis and acute exacerbations of
chronic bronchitis, 50 (96.1%) of 52 patients with
PRSP infection, including 13 of 15 isolates with
amoxycillin MICs of 4–8 mg ⁄L, were treated
successfully with amoxycillin–clavulanate 2000 ⁄
125 mg twice-daily [8]. In paediatric phase
III otitis media studies, Augmentin ES-600
(90 ⁄ 6.4 mg ⁄ kg ⁄day) eradicated 31 (91%) of 34
PRSP isolates by the primary endpoint visit
(on-therapy) [9].
In conclusion, in an era of increased resistance
to many of the antimicrobial agents used com-
monly today, treatment options are limited. Peni-
cillin-intermediate and ⁄ or -resistant isolates of
S. pneumoniae that are reported falsely as resistant
to amoxycillin, or amoxycillin-containing formu-
lations, would reduce the availability of treatment
options and could lead to the use of less appro-
priate agents, such as the ﬂuoroquinolones, which
may need to be reserved for treatment failures.
This is a particular concern with paediatric
patients, for whom ﬂuoroquinolones are not
approved for common respiratory tract infections.
Therefore, if surveillance studies on S. pneumoniae
are to be used by clinicians to help determine
therapeutic options, both penicillin and amoxy-
cillin should be tested.
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Performance of the Focus ELISA test for
detection of herpes simplex virus type-
2-speciﬁc antibodies in Chinese STD
patients
Herpes simplex virus type-2 (HSV-2) infection is
one of the most common sexually transmitted
infections, with a signiﬁcantly increased inci-
dence worldwide. Effective intervention has been
complicated, in part, by the absence of methods
to differentiate HSV-1- from HSV-2-infected
individuals accurately and easily. During the
past 15 years, many tests for detecting antibodies
to HSV-1 or HSV-2 have been developed. The
recent article by Ashley-Morrow et al. [1] des-
cribed the performance of the HerpeSelect HSV-2
ELISA (Focus Technologies, Cypress, CA, USA)
in ten different geographical locations. This test
has been introduced into sexually transmitted
disease (STD) services in China, and has also
been used in epidemiological and interventional
projects.
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In order to determine the performance, and
particularly the sensitivity and speciﬁcity, of the
Focus HSV-2 ELISA in Chinese STD settings, 105
serum specimens were collected from patients
attending the STD Clinic of the Chinese Academy
of Medical Sciences, and the Peking Union Med-
ical College Institute of Dermatology. The results
obtained with the Focus HSV-2 ELISA were
compared with those determined by the Western
blot method.
The seroprevalence of HSV-2, as determined by
Western blot, was 55.2% (58 ⁄ 105 specimens) in
the study population. The Focus HSV-2 ELISA
and Western blot results were concordant (both
negative or both positive) for 89.5% of the 105
specimens, with 92.0% sensitivity and 95.7%
speciﬁcity, and positive and negative predictive
values of 95.8% and 91.7%, respectively, if spec-
imens with equivocal ELISA results were exclu-
ded from the calculation. The sensitivity and
speciﬁcity were 79.3% and 95.7%, respectively, if
the samples with equivocal ELISA results were
considered negative, and were 93.1% and 93.6%,
respectively, if the samples with equivocal ELISA
results were considered positive. Analysis with a
receiver operator characteristic curve demonstra-
ted that the best index cut-off value to optimise
the assay performance in this population was 0.9,
with a sensitivity of 93.1% (95% CI, 83.3–98.0%)
and a speciﬁcity of 93.6% (95% CI, 82.4–98.6%).
If the manufacturer’s recommended index cut-off
value of 1.1 was used, the sensitivity was only
79.3%.
In summary, the sensitivity and speciﬁcity of
the Focus HSV-2 ELISA in a Chinese STD popu-
lation were satisfactory but, compared with other
countries, a lower index cut-off value might be
required for optimal sensitivity and speciﬁcity.
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Immunisation against tick-borne
encephalitis by widely used vaccines:
short-term history and current
recommendations
Tick-borne encephalitis (TBE) virus, transmitted
by ticks, remains a serious health problem in
central ⁄ eastern Europe and Asia. TBE virus is a
member of the Flavivirus family. The biology of
the main vector ticks, Ixodes ricinus and Ixodes
persulcatus, is understood in so far as it is clinically
relevant [1]. In the recent article by Charrel et al.
[2], the authors state that vaccination is the most
important means of prevention of TBE. In this
context, the authors provide an overview of
available TBE vaccines. However, the data provi-
ded do not include important information regard-
ing recent TBE vaccine developments and
discussions on TBE immunisation schedules for
primary and booster immunisation.
Two commercially available vaccines and their
formulations are currently used widely in central
and eastern Europe, namely new versions of
Encepur (Chiron Vaccines, Marburg, Germany)
and FSME-IMMUN (Baxter Vaccines, Vienna,
Austria) (Table 1). The development of an inacti-
vated vaccine was initiated in 1971. Various
versions of this ﬁrst TBE vaccine (FSME-IMMUN)
have been approved since 1976. In 1999, the
preservative thiomersal was removed, and a new
formulation, free of thiomersal and human serum
albumin (TicoVac), was introduced in 2000. How-
ever, an increased rate of reported cases of
high fever and febrile convulsions in children
was noted. Human albumin was subsequently
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